<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fenfluramine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fenfluramine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fenfluramine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="128557" href="/d/html/128557.html" rel="external">see "Fenfluramine: Drug information"</a> and <a class="drug drug_patient" data-topicid="128886" href="/d/html/128886.html" rel="external">see "Fenfluramine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F54501042"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Valvular heart disease and pulmonary arterial hypertension</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">There is an association between serotonergic drugs with 5-HT2B receptor agonist activity, including fenfluramine, and valvular heart disease and pulmonary arterial hypertension. Echocardiogram assessments are required before, during, and after treatment with fenfluramine. The benefits vs the risks of initiating or continuing fenfluramine must be considered, based on echocardiogram findings. Because of the risks of valvular heart disease and pulmonary arterial hypertension, fenfluramine is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the FINTEPLA REMS.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F54506790"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Fintepla</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F54736924"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiseizure Agent, Miscellaneous</span>;</li>
<li>
<span class="list-set-name">Serotonin 5HT-2 Receptor Agonist</span></li></ul></div>
<div class="block dop drugH1Div" id="F54526201"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Prior to initiation, obtain an echocardiogram assessment to rule out valvular heart disease and pulmonary arterial hypertension.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="97968626-0187-4ded-bbbe-e033b2219dba">Dravet syndrome–associated seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dravet syndrome–associated seizures:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients <b>not</b></i>
<i>taking stiripentol: </i>Oral: Initial: 0.1 mg/kg/dose twice daily; may increase based on response and tolerability after 7 days to 0.2 mg/kg/dose twice daily; may further increase based on response and tolerability after 7 days to 0.35 mg/kg/dose twice daily. Maximum daily dose: 26 mg/<b>day</b>.<b> Note:</b> If a more rapid titration is warranted, the dose may be increased every 4 days (only in patients <i>not</i> receiving concomitant stiripentol).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients taking stiripentol: </i>Oral: Initial: 0.1 mg/kg/dose twice daily; may increase based on response and tolerability after 7 days to 0.15 mg/kg/dose twice daily; may further increase based on response and tolerability after 7 days to 0.2 mg/kg/dose twice daily. Maximum daily dose: 17 mg/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d15ddbe5-8232-4aaf-8c74-9510fa55706b">Lennox-Gastaut syndrome–associated seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lennox-</b>
<b>Gastaut syndrome–associated seizures: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients <b>not</b></i>
<i>taking stiripentol: </i>Oral: Initial: 0.1 mg/kg/dose twice daily for 1 week; on day 7, increase as tolerated to 0.2 mg/kg/dose twice daily for 1 week; then on day 14 increase as tolerated to the recommended maintenance dose of 0.35 mg/kg/dose twice daily. Maximum daily dose: 26 mg/<b>day</b>. <b>Note:</b> If a more rapid titration is warranted, the dose may be increased every 4 days (only in patients <i>not </i>receiving concomitant stiripentol).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients taking stiripentol: </i>Oral: Initial: 0.1 mg/kg/dose twice daily for 1 week; on day 7, increase as tolerated to 0.15 mg/kg/dose twice daily for 1 week; then on day 14 increase as tolerated to the recommended maintenance dose of 0.35 mg/kg/dose twice daily. Maximum daily dose: 17 mg/<b>day</b>.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b> Gradually decrease the dose to discontinue; abrupt discontinuation may result in increased seizure frequency or status epilepticus.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F54526202"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustments are necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR 15 to 29 mL/minute/1.73 m<sup>2</sup>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients <b>not</b> receiving stiripentol</i>: Maximum daily dose: 20 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients receiving stiripentol</i>: Maximum daily dose: 17 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;15 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F54526205"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥2 years and Adolescents: Mild to severe impairment: Use is not recommended.</p></div>
<div class="block doa drugH1Div" id="F54526112"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="128557" href="/d/html/128557.html" rel="external">see "Fenfluramine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="97968626-0187-4ded-bbbe-e033b2219dba">Dravet syndrome–associated seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dravet syndrome–associated seizures:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients <b>not</b></i>
<i>taking stiripentol</i>
<i>: </i>
<b>Oral: </b>Initial: 0.1 mg/kg twice daily; may increase based on response and tolerability after 7 days to 0.2 mg/kg twice daily; may further increase based on response and tolerability after 7 days to 0.35 mg/kg twice daily. Maximum dose: 26 mg/day.<b> Note:</b> If a more rapid titration is warranted, the dose may be increased every 4 days (only in patients <i>not</i> receiving concomitant stiripentol).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients taking stiripentol: </i>
<b>Oral: </b>Initial: 0.1 mg/kg twice daily; may increase based on response and tolerability after 7 days to 0.15 mg/kg twice daily; may further increase based on response and tolerability after 7 days to 0.2 mg/kg twice daily. Maximum dose: 17 mg/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d15ddbe5-8232-4aaf-8c74-9510fa55706b">Lennox-Gastaut syndrome–associated seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lennox-Gastaut syndrome–associated seizures:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients </i>
<b>
<i>not</i></b>
<i>taking stiripentol: </i>
<b>Oral: </b>Initial: 0.1 mg/kg twice daily; Day 7: Increase as tolerated to 0.2 mg/kg twice daily; Day 14: Increase as tolerated to 0.35 mg/kg twice daily. Maximum dose: 26 mg/day. <b>Note:</b> If a more rapid titration is warranted, the dose may be increased every 4 days (only in patients <i>not </i>receiving concomitant stiripentol).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients taking stiripentol: </i>
<b>Oral:</b> Initial: 0.1 mg/kg twice daily; Day 7: Increase as tolerated to 0.15 mg/kg twice daily; Day 14: Increase as tolerated to 0.2 mg/kg twice daily. Maximum dose: 17 mg/day.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Discontinuation of therapy: </i>Withdraw gradually to minimize the potential of increased seizure frequency.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Dosage adjustment for concomitant therapy</b>
<b>: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F54526114"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustments are necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR 15 to 29 mL/minute/1.73 m<sup>2</sup>:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients not receiving stiripentol</i>: Maximum dose: 20 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients receiving stiripentol plus clobazam</i>: Maximum dose: 17 mg/day.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR &lt;15 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F54526115"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (Child-Pugh class A):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients not receiving stiripentol</i>: Maximum dose: 20 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients receiving stiripentol plus clobazam</i>: Maximum dose: 13 mg/day.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate impairment (Child-Pugh class B):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients not receiving stiripentol</i>: Maximum dose: 20 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients receiving stiripentol plus clobazam</i>: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients not receiving stiripentol</i>: Maximum dose: 17 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients receiving stiripentol plus clobazam</i>: Use is not recommended.</p></div>
<div class="block arsc drugH1Div" id="F55044160"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Blood pressure increased</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Increased blood pressure</b> has been reported; hypertensive crisis has also been observed in adults receiving fenfluramine, including patients without a history of hypertension; there were no cases of hypertensive crisis in patients receiving fenfluramine for Dravet syndrome or Lennox-Gastaut syndrome in trials up to 3 years duration<b>. </b></p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pulmonary arterial hypertension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary hypertension </b>(arterial) has been associated with fenfluramine when previously marketed at higher doses for weight loss in adults (and withdrawn from the market in 1997). In current trials of fenfluramine for Dravet syndrome or Lennox-Gastaut syndrome up to 3 years duration, there were no reports of pulmonary arterial hypertension (PAH) in patients receiving fenfluramine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31862249']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31862249'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unclear; however, serotonin receptor 5HT-2 agonist activity promotes both vasoconstriction and remodeling of pulmonary vasculature, resulting in a thickening of the medial layer and a narrowing of the lumen of the pulmonary artery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18536742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18536742'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; based on a retrospective trial of previous case reports of PAH associated with fenfluramine-derivatives for weight loss, the median onset of symptoms was 4.5 years in patients with a median duration of therapy of 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17959632']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17959632'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Based on previous data when fenfluramine was used as an appetite suppressant for weight loss:</p>
<p style="text-indent:-2em;margin-left:8em;">• Family history of pulmonary hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8692238']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8692238'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Duration of use (&gt;3 to 6 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8692238','lexi-content-ref-31862249','lexi-content-ref-17959632']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8692238','lexi-content-ref-31862249','lexi-content-ref-17959632'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Serotonin syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serotonin syndrome may occur, particularly when used in combination with other serotonergic agents or agents that impair metabolism of serotonin. The diagnosis of serotonin syndrome is made based on the Hunter Serotonin Toxicity Criteria (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12925718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12925718'])">Ref</a></span>) and may result in a spectrum of symptoms, such as anxiety, agitation, confusion, delirium, hyperreflexia, muscle rigidity, myoclonus, tachycardia, tachypnea, and tremor. Severe cases may cause hyperthermia, significant autonomic instability (ie, rapid and severe changes in blood pressure and pulse), coma, and seizures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28148614','lexi-content-ref-15784664','lexi-content-ref-18759711']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28148614','lexi-content-ref-15784664','lexi-content-ref-18759711'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; overstimulation of serotonin receptors by serotonergic agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28148614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28148614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; onset of serotonin syndrome is typically within hours of exposure but delays of ≥24 hours have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28148614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28148614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of drugs that increase serotonin synthesis, block serotonin reuptake, and/or impair serotonin metabolism</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Valvular heart disease</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fenfluramine has been associated with valvular heart disease when previously marketed at higher doses for weight loss in adults, and this concern led to its withdrawal from the US market in 1997 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23769407']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23769407'])">Ref</a></span>). In current trials in patients receiving fenfluramine for Dravet syndrome, trace <b>aortic insufficiency </b>and <b>mitral valve insufficiency</b>, considered to be within the normal physiologic range, have commonly been observed; no cases of valvular heart disease were observed in studies for Dravet syndrome or Lennox-Gastaut syndrome up to 3 years duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31862249']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31862249'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; likely due to activation of serotonin 5HT-<sub>2B </sub>receptors; 5HT-<sub>2B </sub>receptors are abundantly expressed on aortic and mitral valves, and these receptors are known to stimulate mitogenesis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23769407','lexi-content-ref-19505264']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23769407','lexi-content-ref-19505264'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; cases have been reported within months to years after drug discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23769407']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23769407'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Based on previous data when fenfluramine was used as an appetite suppressant for weight loss:</p>
<p style="text-indent:-2em;margin-left:8em;">• High doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31862249','lexi-content-ref-19505264']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31862249','lexi-content-ref-19505264'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Duration of use (≥3 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23769407','lexi-content-ref-31862249','lexi-content-ref-19505264','lexi-content-ref-12486432']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23769407','lexi-content-ref-31862249','lexi-content-ref-19505264','lexi-content-ref-12486432'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Coadministration with other medications known to be 5HT-<sub>2B </sub>receptor agonists (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19505264']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19505264'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Weight loss</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fenfluramine causes <b>decreased appetite </b>and significant <b>weight loss</b> (≥7% from baseline); during open-label extension studies, approximately half of patients resumed expected measured increases in weight.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related (likely); as a derivative of amphetamine, it is believed the anorectic effect is mediated through its serotonergic effects, leading to increased 5-HT in the brain and resulting in decreased appetite (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26600876']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26600876'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F54513718"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in children, adolescents, and adults and may include rates with concurrent antiseizure medications.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Aortic insufficiency (18% to 23%; including aortic regurgitation) (Lagae 2020)<span class="lexi-table-link-container"> (<a aria-label="Fenfluramine: Adverse Reaction: Aortic Insufficiency table link" class="lexi-table-link" data-table-id="lexi-content-fenfluramine-adverse-reaction-aortic-insufficiency" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-fenfluramine-adverse-reaction-aortic-insufficiency')">table 1</a>)</span><span class="table-link" style="display:none;">Fenfluramine: Adverse Reaction: Aortic Insufficiency</span>, increased blood pressure (8% to 13%)<span class="lexi-table-link-container"> (<a aria-label="Fenfluramine: Adverse Reaction: Increased Blood Pressure table link" class="lexi-table-link" data-table-id="lexi-content-fenfluramine-adverse-reaction-increased-blood-pressure" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-fenfluramine-adverse-reaction-increased-blood-pressure')">table 2</a>)</span><span class="table-link" style="display:none;">Fenfluramine: Adverse Reaction: Increased Blood Pressure</span>, mitral valve insufficiency (18% to 23%; including mitral regurgitation and mitral stenosis) (Ennezat 2021; Lagae 2020)<span class="lexi-table-link-container"> (<a aria-label="Fenfluramine: Adverse Reaction: Mitral Valve Insufficiency table link" class="lexi-table-link" data-table-id="lexi-content-fenfluramine-adverse-reaction-mitral-valve-insufficiency" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-fenfluramine-adverse-reaction-mitral-valve-insufficiency')">table 3</a>)</span><span class="table-link" style="display:none;">Fenfluramine: Adverse Reaction: Mitral Valve Insufficiency</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Fenfluramine: Adverse Reaction: Aortic Insufficiency" frame="border" id="lexi-content-fenfluramine-adverse-reaction-aortic-insufficiency" rules="all">
<caption style="text-align:center;">
<b>Fenfluramine: Adverse Reaction: Aortic Insufficiency</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="left"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Fenfluramine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;">Indication</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Fenfluramine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Source</b></p></th>
<th align="left" valign="top">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.7 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;">Dravet syndrome</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Lagae 2020</p></td>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Trace and within the normal physiological range</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.2 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;">Dravet syndrome</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">39</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Lagae 2020</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Fenfluramine: Adverse Reaction: Increased Blood Pressure" frame="border" id="lexi-content-fenfluramine-adverse-reaction-increased-blood-pressure" rules="all">
<caption style="text-align:center;">
<b>Fenfluramine: Adverse Reaction: </b>
<b>Increased Blood Pressure</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="left"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Fenfluramine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;">Indication</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Fenfluramine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.2 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;">Dravet syndrome</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">39</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">84</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.7 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;">Dravet syndrome</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">84</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Fenfluramine: Adverse Reaction: Mitral Valve Insufficiency" frame="border" id="lexi-content-fenfluramine-adverse-reaction-mitral-valve-insufficiency" rules="all">
<caption style="text-align:center;">
<b>Fenfluramine: Adverse Reaction: </b>
<b>Mitral Valve Insufficiency</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="left"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Fenfluramine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;">Indication</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Fenfluramine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Source</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.7 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;">Dravet syndrome</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Lagae 2020</p></td>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Trace and within the normal physiological range</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.2 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;">Dravet syndrome</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">39</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Lagae 2020</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight loss (2% to 13%)<span class="lexi-table-link-container"> (<a aria-label="Fenfluramine: Adverse Reaction: Weight Loss table link" class="lexi-table-link" data-table-id="lexi-content-fenfluramine-adverse-reaction-weight-loss" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-fenfluramine-adverse-reaction-weight-loss')">table 4</a>)</span><span class="table-link" style="display:none;">Fenfluramine: Adverse Reaction: Weight Loss</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Fenfluramine: Adverse Reaction: Weight Loss" frame="border" id="lexi-content-fenfluramine-adverse-reaction-weight-loss" rules="all">
<caption style="text-align:center;">
<b>Fenfluramine: Adverse Reaction: </b>
<b>Weight Loss</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="left"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Fenfluramine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;">Indication</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Fenfluramine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.2 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;">Dravet syndrome</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">39</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">84</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.7 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;">Dravet syndrome</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">84</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.7 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;">Lennox-Gastaut syndrome</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">87</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">87</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.2 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;">Lennox-Gastaut syndrome</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">89</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">87</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Decreased appetite (20% to 38%)<span class="lexi-table-link-container"> (<a aria-label="Fenfluramine: Adverse Reaction: Decreased Appetite table link" class="lexi-table-link" data-table-id="lexi-content-fenfluramine-adverse-reaction-decreased-appetite" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-fenfluramine-adverse-reaction-decreased-appetite')">table 5</a>)</span><span class="table-link" style="display:none;">Fenfluramine: Adverse Reaction: Decreased Appetite</span>, diarrhea (11% to 31%), sialorrhea (≤13%), vomiting (8% to 14%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Fenfluramine: Adverse Reaction: Decreased Appetite" frame="border" id="lexi-content-fenfluramine-adverse-reaction-decreased-appetite" rules="all">
<caption style="text-align:center;">
<b>Fenfluramine: Adverse Reaction: </b>
<b>Decreased Appetite</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="left"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Fenfluramine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;">Indication</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Fenfluramine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">38%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.7 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;">Dravet syndrome</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">84</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.2 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;">Dravet syndrome</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">39</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">84</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">36%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.7 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;">Lennox-Gastaut syndrome</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">87</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">87</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.2 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;">Lennox-Gastaut syndrome</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">89</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">87</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (≤24%), drooling (≤13%), drowsiness (≤26%), fatigue (≤24%), lethargy (≤26%), malaise (≤24%), sedated state (≤26%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (7% to 21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (15%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Increased heart rate (3% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration (5%), increased serum prolactin (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (3% to 10%), gastroenteritis (3% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary incontinence (3% to 5%), urinary tract infection (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal behavior (8%; stereotypy: 5%), abnormal gait (≤10%), ataxia (≤10%), balance impairment (≤10%), chills (5%), falling (10%), headache (8%), hypoactivity (5%), hypotonia (8%), insomnia (5%), irritability (3% to 8%), mood changes (negativism: 5%), status epilepticus (3%), tremor (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Rhinitis (3% to 8%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Heart valve disease (when previously marketed at higher doses for weight loss in adults), hypertensive crisis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pulmonary hypertension (arterial; when previously marketed at higher doses for weight loss in adults)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Nervous system: Aggressive behavior</p></div>
<div class="block coi drugH1Div" id="F54501046"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to fenfluramine or any component of the formulation; concomitant use with or within 14 days of monoamine oxidase inhibitors.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F54526099"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular effects: May cause mild pupillary dilation, which, in susceptible individuals, can lead to an episode of angle-closure glaucoma. Consider discontinuing fenfluramine in patients with acute decreases in visual acuity or ocular pain.</p>
<p style="text-indent:-2em;margin-left:4em;">• Suicidal ideation: Pooled analysis of trials involving various antiseizure medications (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials ≤24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify health care provider immediately if symptoms occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• REMS program:<b></b>Counsel patients about the risks, signs and symptoms, and required monitoring for valvular heart disease and pulmonary arterial hypertension.</p>
<p style="text-indent:-2em;margin-left:4em;">• Withdrawal: Antiseizure medications should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.</p></div>
<div class="block foc drugH1Div" id="F54506791"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fintepla: 2.2 mg/mL (30 mL, 360 mL) [gluten free; contains ethylparaben, methylparaben; cherry flavor]</p></div>
<div class="block geq drugH1Div" id="F54506789"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F54678287"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Fintepla Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.2 mg/mL (per mL): $64.41</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F54526203"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be administered without regard to meals using provided oral syringe; do not use a household teaspoon (overdosage may occur). May also be administered via gastric or nasogastric tube.</p></div>
<div class="block adm drugH1Div" id="F54526116"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with or without food using the provided calibrated oral syringe (3 mL or 6 mL); do not use a household teaspoon or tablespoon (overdosage may occur).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Enteral:</b> May be administered via gastric and nasogastric feeding tubes.</p></div>
<div class="block sts drugH1Div" id="F54526101"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store between 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C to 30°C (59°F to 86°F). Do not refrigerate or freeze. Store the bottle and syringe together. Discard any unused portion 3 months after first opening the bottle or the “Discard After” date on the bottle, whichever is sooner.</p></div>
<div class="block meg drugH1Div" id="F54526096"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Fintepla: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F212102s013lbl.pdf%23page%3D30&amp;token=XiuIs1d55dOdWVXpl1zNRLmiQH1%2FRy1Vq6k8qi7c7feS%2FJGayXdZlp2YQyK%2FWnebFYExjcO%2FAsQFSGfc7OHm1Q0aAMhxJ3HeJ71ndTaMITfajMkhnyZMpLpo74PcZMC9&amp;TOPIC_ID=128558" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212102s013lbl.pdf#page=30</a></p></div>
<div class="block usep drugH1Div" id="F54500981"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of seizures associated with Dravet syndrome or Lennox-Gastaut syndrome (FDA approved in ages ≥2 years).</p></div>
<div class="block cyt drugH1Div" id="F54582101"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (major), CYP2B6 (major), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F54582098"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Broccoli: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloBAZam: May increase the serum concentration of Fenfluramine. Management: Limit the fenfluramine dose to a maximum daily dosage of 0.2 mg/kg twice daily (17 mg/day) when used in combination with stiripentol and clobazam.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inhibitors (Strong): May increase the serum concentration of Fenfluramine. Management: Limit fenfluramine dose to 20 mg/day without concurrent stiripentol or to 17 mg/day with concomitant stiripentol and clobazam when used with a strong CYP1A2 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Strong): May increase the serum concentration of Fenfluramine. Management: Limit fenfluramine dose to 20 mg/day without concurrent stiripentol or to 17 mg/day with concomitant stiripentol and clobazam when used with a strong CYP2D6 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Fenfluramine. Management: Avoid concurrent use of strong CYP3A4 inducers with fenfluramine when possible. If combined use cannot be avoided, consider increasing the fenfluramine dose, but do not exceed the fenfluramine maximum daily dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyproheptadine: Fenfluramine may enhance the CNS depressant effect of Cyproheptadine. Cyproheptadine may diminish the therapeutic effect of Fenfluramine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May decrease the serum concentration of CYP2B6 Substrates (High risk with Inducers). Management: Avoid concomitant use of fexinidazole and CYP2B6 substrates when possible. If combined, monitor for reduced efficacy of the CYP2B6 substrate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: Fenfluramine may enhance the serotonergic effect of Linezolid. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorcaserin (Withdrawn From US Market): May enhance the serotonergic effect of Serotonergic Agents (Moderate Risk, Miscellaneous). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylene Blue: Fenfluramine may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors (Antidepressant): Fenfluramine may enhance the serotonergic effect of Monoamine Oxidase Inhibitors (Antidepressant). This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors (Type B): Fenfluramine may enhance the serotonergic effect of Monoamine Oxidase Inhibitors (Type B). This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Fenfluramine. Management: Avoid concurrent use of rifampin with fenfluramine when possible. If combined use cannot be avoided, consider increasing the fenfluramine dose, but do not exceed the fenfluramine maximum daily dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): Fenfluramine may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (Moderate Risk, Miscellaneous): Fenfluramine may enhance the serotonergic effect of Serotonergic Agents (Moderate Risk, Miscellaneous). This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Stiripentol: May increase the serum concentration of Fenfluramine. Management: If coadministered with stiripentol and clobazam, initate fenfluramine at 0.1 mg/kg twice daily, then on day 7 increase fenfluramine to 0.15 mg/kg twice daily, and on day 14 increase fenfluramine to 0.2 mg/kg twice daily. Max dose 17 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F54526097"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Information related to inadvertent maternal use of fenfluramine in pregnancy is available from previous reports when used to treat obesity (Jones 2002; Vial 1992). Fenfluramine is associated with an increased risk of pulmonary arterial hypertension, which has also been reported following exposure in pregnancy (Bonnin 2005).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to antiseizure drugs is ongoing. Patients exposed to fenfluramine during pregnancy are encouraged to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry (888-233-2334 or http://www.aedpregnancyregistry.org).</p></div>
<div class="block mopp drugH1Div" id="F54526204"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;">Echocardiogram (baseline and every 6 months during therapy; 3 to 6 months following discontinuation); growth and weight; blood pressure; vision or eye changes; seizure frequency, duration, and severity; signs and symptoms of serotonin syndrome in patients receiving concomitant serotonergic agents (eg, mental status changes, hyperthermia, tachycardia, hyperreflexia, GI symptoms); emergence or worsening depression and suicidality (eg, suicidal thoughts, depression, behavioral changes).</p></div>
<div class="block pha drugH1Div" id="F54526102"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">The mechanisms by which fenfluramine exerts its therapeutic effects in the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome are unknown. Fenfluramine and the metabolite, norfenfluramine, increase extracellular levels of serotonin through interaction with serotonin transporter proteins, and exhibit agonist activity at serotonin 5HT-2 receptors.</p></div>
<div class="block phk drugH1Div" id="F54526103"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Pharmacokinetic parameters in pediatric patients are reported to be similar to those in healthy adult subjects.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>z</sub>/F: 11.9 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 50%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: 75% is metabolized primarily by CYP1A2, CYP2B6, and CYP2D6 to active metabolite norfenfluramine; CYP2C9, CYP2C19, and CYP2D6 are involved to a minor extent. Norfenfluramine is deaminated and oxidized to inactive metabolites.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~68% to 74%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 20 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 3 to 5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine: &gt;90% (&lt;25% as unchanged drug or active metabolite); feces: &lt;5%.</p></div>
<div class="block phksp drugH1Div" id="F57828608"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: In patients with severe renal impairment (eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>, C<sub>max</sub> and AUC of fenfluramine increased by 20% and 88%, respectively, and C<sub>max</sub> and AUC of norfenfluramine increased by 13% and 21%, respectively, following a single 0.35 mg/kg dose. Has not been studied in eGFR &lt;15 mL/minute/1.73 m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: In patients with mild, moderate, or severe hepatic impairment (Child-Pugh class A, B, and C), AUC of fenfluramine increased by 95%, 113%, and 185%, respectively, and C<sub>max</sub> of fenfluramine increased by 19%, 16%, and 29%, respectively, compared to patients with normal hepatic function, following a single 0.35 mg/kg/dose. AUC of norfenfluramine increased by 18% in mild hepatic impairment and 4% in moderate hepatic impairment, but decreased by 11% in severe hepatic impairment and C<sub>max</sub> of norfenfluramine decreased by 21%, 36%, and 45% in patients with mild, moderate, and severe hepatic impairment, respectively, compared to patients with normal hepatic function, following a single 0.35 mg/kg/dose. The combined molar AUC of fenfluramine and norfenfluramine increased by 55%, 56%, and 82%, and the combined molar C<sub>max</sub> of fenfluramine and norfenfluramine increased by 7.5%, 1.3%, and 8% in patients with mild, moderate, and severe hepatic impairment, respectively, compared to patients with normal hepatic function, following a single 0.35 mg/kg/dose.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56755113"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Fintepla</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Fintepla</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Fenfluramine</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Fintepla</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Fintepla</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Fintepla</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Fintepla</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Fintepla</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Fintepla</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Fintepla</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-8692238">
<a name="8692238"></a>Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. <i>N Engl J Med</i>. 1996;335(9):609-616. doi:10.1056/NEJM199608293350901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenfluramine-pediatric-drug-information/abstract-text/8692238/pubmed" id="8692238" target="_blank">8692238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23769407">
<a name="23769407"></a>Andrejak M, Tribouilloy C. Drug-induced valvular heart disease: an update. <i>Arch Cardiovasc Dis</i>. 2013;106(5):333-339. doi:10.1016/j.acvd.2013.02.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenfluramine-pediatric-drug-information/abstract-text/23769407/pubmed" id="23769407" target="_blank">23769407</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28148614">
<a name="28148614"></a>Bartlett D. Drug-induced serotonin syndrome. <i>Crit Care Nurse</i>. 2017;37(1):49-54. doi:10.4037/ccn2017169<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenfluramine-pediatric-drug-information/abstract-text/28148614/pubmed" id="28148614" target="_blank">28148614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15915025">
<a name="15915025"></a>Bonnin M, Mercier FJ, Sitbon O, et al. Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. <i>Anesthesiology</i>. 2005;102(6):1133-1137. doi:10.1097/00000542-200506000-00012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenfluramine-pediatric-drug-information/abstract-text/15915025/pubmed" id="15915025" target="_blank">15915025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15784664">
<a name="15784664"></a>Boyer EW, Shannon M. The serotonin syndrome. <i>N Engl J Med</i>. 2005;352(11):1112-1120. doi:10.1056/NEJMra041867. Erratum in: <i>N Engl J Med</i>. 2007;356(23):2437. Erratum in: <i>N Engl J Med</i>. 2009;361(17):1714.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenfluramine-pediatric-drug-information/abstract-text/15784664/pubmed" id="15784664" target="_blank">15784664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18536742">
<a name="18536742"></a>Dempsie Y, MacLean MR. Pulmonary hypertension: therapeutic targets within the serotonin system. <i>Br J Pharmacol</i>. 2008;155(4):455-462. doi:10.1038/bjp.2008.241<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenfluramine-pediatric-drug-information/abstract-text/18536742/pubmed" id="18536742" target="_blank">18536742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12925718">
<a name="12925718"></a>Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: Simple and accurate diagnostic decision rules for serotonin toxicity. <i>QJM</i>. 2003;96(9):635-642. doi:10.1093/qjmed/hcg109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenfluramine-pediatric-drug-information/abstract-text/12925718/pubmed" id="12925718" target="_blank">12925718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fintepla.1">
<a name="Fintepla.1"></a>Fintepla (fenfluramine) [prescribing information]. Smyrna, GA: UCB Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fintepla.1">
<a name="Fintepla.1"></a>Fintepla (fenfluramine) [prescribing information]. Smyrna, GA: UCB Inc; December 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11877776">
<a name="11877776"></a>Jones KL, Johnson KA, Dick LM, Felix RJ, Kao KK, Chambers CD. Pregnancy outcomes after first trimester exposure to phentermine/fenfluramine. <i>Teratology</i>. 2002;65(3):125-130. doi:10.1002/tera.10023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenfluramine-pediatric-drug-information/abstract-text/11877776/pubmed" id="11877776" target="_blank">11877776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31862249">
<a name="31862249"></a>Lagae L, Sullivan J, Knupp K, et al; FAiRE DS Study Group. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. <i>Lancet</i>. 2019;394(10216):2243-2254. doi:10.1016/S0140-6736(19)32500-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenfluramine-pediatric-drug-information/abstract-text/31862249/pubmed" id="31862249" target="_blank">31862249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19505264">
<a name="19505264"></a>Rothman RB, Baumann MH. Serotonergic drugs and valvular heart disease. <i>Expert Opin Drug Saf</i>. 2009;8(3):317-329. doi:10.1517/14740330902931524<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenfluramine-pediatric-drug-information/abstract-text/19505264/pubmed" id="19505264" target="_blank">19505264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12486432">
<a name="12486432"></a>Sachdev M, Miller WC, Ryan T, Jollis JG. Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies. <i>Am Heart J</i>. 2002;144(6):1065-1073. doi:10.1067/mhj.2002.126733<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenfluramine-pediatric-drug-information/abstract-text/12486432/pubmed" id="12486432" target="_blank">12486432</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26600876">
<a name="26600876"></a>Schoonjans AS, Lagae L, Ceulemans B. Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome. <i>Ther Adv Neurol Disord</i>. 2015;8(6):328-338. doi:10.1177/1756285615607726<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenfluramine-pediatric-drug-information/abstract-text/26600876/pubmed" id="26600876" target="_blank">26600876</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17959632">
<a name="17959632"></a>Souza R, Humbert M, Sztrymf B, et al. Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. <i>Eur Respir J</i>. 2008;31(2):343-348. doi:10.1183/09031936.00104807. Erratum in: <i>Eur Respir J</i>. 2008;31(4):912.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenfluramine-pediatric-drug-information/abstract-text/17959632/pubmed" id="17959632" target="_blank">17959632</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18759711">
<a name="18759711"></a>Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. <i>Expert Opin Drug Saf</i>. 2008;7(5):587-596. doi:10.1517/14740338.7.5.587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenfluramine-pediatric-drug-information/abstract-text/18759711/pubmed" id="18759711" target="_blank">18759711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23511002">
<a name="23511002"></a>Vial T, Robert E, Carlier P, Bertolotti E, Brun A. First-trimester in utero exposure to anorectics: a French collaborative study with special reference to dexfenfluramine. <i>Int J Risk Saf Med</i>. 1992;3(4):207-214. doi:10.3233/JRS-1992-3404<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenfluramine-pediatric-drug-information/abstract-text/23511002/pubmed" id="23511002" target="_blank">23511002</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 128558 Version 104.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
